ZA200800180B - Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative - Google Patents

Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative

Info

Publication number: ZA200800180B
Authority: ZA; South Africa
Prior art keywords: prevention; treatment; liver diseases; pyrazolopyrimidine derivative; present
Prior art date: 2005-06-10

Application number

ZA200800180A

Other languages

English (en)

Inventor

Ahn Byoung Ok

Choi Seul Min

Yoo Moohi

Original Assignee

Dong A Pharm Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-10

Filing date

2008-01-08

Publication date

2009-01-28

2008-01-08 Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd

2009-01-28 Publication of ZA200800180B publication Critical patent/ZA200800180B/xx

Links

208000019423 liver disease Diseases 0.000 title abstract 3
230000002265 prevention Effects 0.000 title abstract 3
DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical class N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 title 1
OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 abstract 4
206010019668 Hepatic fibrosis Diseases 0.000 abstract 2
208000007232 portal hypertension Diseases 0.000 abstract 2
210000003240 portal vein Anatomy 0.000 abstract 2
102000008186 Collagen Human genes 0.000 abstract 1
108010035532 Collagen Proteins 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000017531 blood circulation Effects 0.000 abstract 1
208000019425 cirrhosis of liver Diseases 0.000 abstract 1
229920001436 collagen Polymers 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
210000004024 hepatic stellate cell Anatomy 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

ZA200800180A 2005-06-10 2008-01-08 Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative ZA200800180B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
KR20050050033		2005-06-10

Publications (1)

Publication Number	Publication Date
ZA200800180B true ZA200800180B (en)	2009-01-28

Family

ID=37498629

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200800180A ZA200800180B (en)	2005-06-10	2008-01-08	Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative

Country Status (22)

Country	Link
US (1)	US8796286B2 (ja)
EP (1)	EP1888074B1 (ja)
JP (1)	JP4879977B2 (ja)
KR (1)	KR100914445B1 (ja)
CN (1)	CN101193636B (ja)
AT (1)	ATE537832T1 (ja)
AU (1)	AU2005332719B2 (ja)
BR (1)	BRPI0520209A2 (ja)
CA (1)	CA2611638C (ja)
CY (1)	CY1112637T1 (ja)
DK (1)	DK1888074T3 (ja)
ES (1)	ES2376628T3 (ja)
HK (1)	HK1119596A1 (ja)
IL (1)	IL187678A (ja)
MX (1)	MX2007015365A (ja)
NO (1)	NO20076053L (ja)
NZ (1)	NZ564369A (ja)
PT (1)	PT1888074E (ja)
RU (1)	RU2369392C2 (ja)
UA (1)	UA86528C2 (ja)
WO (1)	WO2006132460A1 (ja)
ZA (1)	ZA200800180B (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2101809B1 (en) *	2006-12-28	2011-10-19	Insect Biotech Co., Ltd.	Pharmaceutical composition containing arazyme for the prevention of liver dysfunction
WO2010118367A2 (en) *	2009-04-10	2010-10-14	Progenics Pharmaceuticals, Inc.	Antiviral pyrimidines
AU2011279144A1 (en) *	2010-07-14	2013-01-24	Cumberland Emerging Technologies, Inc	Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists
JP6235583B2 (ja) *	2012-07-11	2017-11-22	ユニバーシティーオブミシシッピメディカルセンター	画像獲得データから肝線維症を検出及びステージ決定する方法
AU2015258805B2 (en)	2014-05-16	2018-05-10	Cumberland Pharmaceuticals, Inc.	Compositions and methods of treating cardiac fibrosis with ifetroban
JP7033454B2 (ja)	2015-06-30	2022-03-10	カンバーランドファーマシューティカルズ，インコーポレーテッド	Ａｅｒｄ／喘息におけるトロンボキサン受容体拮抗薬
ES2955158T3 (es)	2016-05-11	2023-11-29	Cumberland Pharmaceuticals Inc	Composiciones y métodos de tratamiento de la distrofia muscular con antagonistas del receptor de tromboxano-A2
CN110833556A (zh) *	2018-08-15	2020-02-25	广西梧州制药（集团）股份有限公司	吡唑并嘧啶衍生物在治疗肝纤维化的用途
CN113493459B (zh) *	2020-04-07	2022-12-13	广州白云山医药集团股份有限公司白云山制药总厂	Pde5抑制剂化合物及其制备方法和应用
AU2022325803A1 (en) *	2021-08-13	2024-03-28	Goldberg, David J.	Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100353014B1 (ko) *	1998-11-11	2002-09-18	동아제약 주식회사	발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
KR100377782B1 (ko)	2000-06-23	2003-03-29	동아제약 주식회사	발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법
US20030216407A1 (en) *	2002-01-31	2003-11-20	Pfizer Inc.	Use of PDE5 inhibitors in the treatment of scarring
GB0202254D0 (en) *	2002-01-31	2002-03-20	Pfizer Ltd	Prevention of scarring
EP1336602A1 (en) *	2002-02-13	2003-08-20	Giovanni Scaramuzzino	Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
GB0214784D0 (en) *	2002-06-26	2002-08-07	Pfizer Ltd	Novel combination
AU2003286555A1 (en)	2002-10-22	2004-05-13	Harbor-Ucla Research And Education Institute	Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
WO2004108662A1 (ja)	2003-05-15	2004-12-16	Kumiai Chemical Industry Co., Ltd.	フェニルスルホニルカーバメイト誘導体及び農園芸用植物病害防除剤
DE10325813B4 (de)	2003-06-06	2007-12-20	Universitätsklinikum Freiburg	Prophylaxe und/oder Therapie bei der portalen Hypertonie
CA2528975A1 (en) *	2003-06-10	2004-12-16	Pfizer Inc.	Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea
DE102005001989A1 (de) *	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren

2005
- 2005-10-21 WO PCT/KR2005/003526 patent/WO2006132460A1/en active Application Filing
- 2005-10-21 BR BRPI0520209-4A patent/BRPI0520209A2/pt not_active IP Right Cessation
- 2005-10-21 CA CA2611638A patent/CA2611638C/en not_active Expired - Fee Related
- 2005-10-21 RU RU2007149474/15A patent/RU2369392C2/ru active
- 2005-10-21 AT AT05808627T patent/ATE537832T1/de active
- 2005-10-21 KR KR1020050099900A patent/KR100914445B1/ko active IP Right Grant
- 2005-10-21 CN CN2005800500656A patent/CN101193636B/zh not_active Expired - Fee Related
- 2005-10-21 JP JP2008515614A patent/JP4879977B2/ja not_active Expired - Fee Related
- 2005-10-21 EP EP05808627A patent/EP1888074B1/en active Active
- 2005-10-21 US US11/916,752 patent/US8796286B2/en active Active
- 2005-10-21 DK DK05808627.3T patent/DK1888074T3/da active
- 2005-10-21 MX MX2007015365A patent/MX2007015365A/es active IP Right Grant
- 2005-10-21 ES ES05808627T patent/ES2376628T3/es active Active
- 2005-10-21 UA UAA200713931A patent/UA86528C2/uk unknown
- 2005-10-21 AU AU2005332719A patent/AU2005332719B2/en not_active Ceased
- 2005-10-21 PT PT05808627T patent/PT1888074E/pt unknown
- 2005-10-21 NZ NZ564369A patent/NZ564369A/en not_active IP Right Cessation
2007
- 2007-11-26 NO NO20076053A patent/NO20076053L/no not_active Application Discontinuation
- 2007-11-27 IL IL187678A patent/IL187678A/en not_active IP Right Cessation
2008
- 2008-01-08 ZA ZA200800180A patent/ZA200800180B/xx unknown
- 2008-11-27 HK HK08112976.5A patent/HK1119596A1/xx not_active IP Right Cessation
2012
- 2012-03-14 CY CY20121100272T patent/CY1112637T1/el unknown

Also Published As

Publication number	Publication date
CA2611638C (en)	2010-08-24
WO2006132460A1 (en)	2006-12-14
JP2008543748A (ja)	2008-12-04
CA2611638A1 (en)	2006-12-14
PT1888074E (pt)	2012-03-01
CN101193636A (zh)	2008-06-04
US8796286B2 (en)	2014-08-05
RU2007149474A (ru)	2009-07-20
US20080207646A1 (en)	2008-08-28
UA86528C2 (uk)	2009-04-27
EP1888074B1 (en)	2011-12-21
KR20060128605A (ko)	2006-12-14
EP1888074A4 (en)	2010-06-23
KR100914445B1 (ko)	2009-08-28
MX2007015365A (es)	2008-02-12
DK1888074T3 (da)	2012-01-23
NO20076053L (no)	2008-02-27
JP4879977B2 (ja)	2012-02-22
RU2369392C2 (ru)	2009-10-10
HK1119596A1 (en)	2009-03-13
CY1112637T1 (el)	2016-02-10
AU2005332719B2 (en)	2010-05-13
BRPI0520209A2 (pt)	2009-04-22
CN101193636B (zh)	2011-12-28
ATE537832T1 (de)	2012-01-15
EP1888074A1 (en)	2008-02-20
AU2005332719A1 (en)	2006-12-14
IL187678A (en)	2013-04-30
NZ564369A (en)	2010-03-26
IL187678A0 (en)	2008-11-03
ES2376628T3 (es)	2012-03-15

Publication	Publication Date	Title
HK1119596A1 (en)	2009-03-13	Use of yrazolopyrimidinone derivative in the preparation of agent for the prevention and treatment of liver diseases
NO20062504L (no)	2006-07-21	Sammensetninger og doseringsformer for forbedret absorpsjon
ATE470443T1 (de)	2010-06-15	Indol-1-yl-essigsäurederivate
NO20042596L (no)	2004-06-21	Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
TW200609227A (en)	2006-03-16	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MY143795A (en)	2011-07-15	Tetrahydropyridoindole derivatives
TW200616650A (en)	2006-06-01	Semi-solid delivery vehicle and pharmaceutical compositions
EA200870216A1 (ru)	2009-02-27	Амидо соединения и их применение в качестве лекарственных средств
DE602006014990D1 (de)	2010-07-29	Intranasale verabreichung von schnell wirkendem insulin
NO20075136L (no)	2007-12-07	Nye liposompreparater
MXPA04004842A (es)	2004-08-02	Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es)	2004-08-02	Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
WO2008039218A3 (en)	2008-05-29	Inhibitors of bruton's tyrosine kinase
GEP20084452B (en)	2008-08-10	Sulfonamide derivatives for the treatment of diseases
WO2005075471A3 (en)	2005-10-06	Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
MX2009011900A (es)	2010-01-20	Curacion de herida diabetica.
WO2007056263A3 (en)	2007-11-08	Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
WO2007056236A3 (en)	2007-09-20	Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2008070010A3 (en)	2008-07-24	Hydroxylamine derivatives for the treatment of stroke
EA200501821A1 (ru)	2006-06-30	Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
RS44204A (en)	2007-06-04	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005065429A3 (en)	2006-02-23	Composition and method for treatment of hepatic encephalopathy
RS44304A (en)	2007-06-04	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL191670A0 (en)	2008-12-29	Compounds for the inhibition of apoptosis
JO2492B1 (en)	2009-10-05	A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients